The rosiglitazone meta-analysis.
作者信息
McCullough Peter A, Lepor Norman E
机构信息
William Beaumont Hospital, Beaumont Health Center, Royal Oak, Michigan, USA.
出版信息
Rev Cardiovasc Med. 2007 Spring;8(2):123-6.
PMID:17603430
Abstract
摘要
相似文献
1
The rosiglitazone meta-analysis.
Rev Cardiovasc Med. 2007 Spring;8(2):123-6.
2
The rosigliazone meta-analysis: lessons for the future.
Diabetes Care. 2008 Mar;31(3):e10. doi: 10.2337/dc07-2147.
3
Faster publication isn't always better.
Nat Clin Pract Cardiovasc Med. 2007 Jul;4(7):345. doi: 10.1038/ncpcardio0942.
4
Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials.
Int J Cardiol. 2010 Aug 20;143(2):135-40. doi: 10.1016/j.ijcard.2009.01.064. Epub 2009 Mar 27.
5
Rosiglitazone, marketing, and medical science.
BMJ. 2010 Apr 7;340:c1848. doi: 10.1136/bmj.c1848.
6
Rosiglitazone and cardiovascular disease: a cardiologist's perspective.
Diab Vasc Dis Res. 2007 Jun;4(2):80-1. doi: 10.3132/dvdr.2007.023.
7
Rosiglitazone and cardiovascular disease: a diabetologist's perspective.
Diab Vasc Dis Res. 2007 Jun;4(2):75-6. doi: 10.3132/dvdr.2007.021.
8
Drug safety. Heart attack risk overshadows a popular diabetes therapy.
Science. 2007 Jun 15;316(5831):1550-1. doi: 10.1126/science.316.5831.1550.
9
Outlook on diabetes drug less than rosy. Early work suggests that rosiglitazone (Avandia) may not be best for the heart.
Harv Heart Lett. 2007 Aug;17(12):1-2.
10
[Rosiglitazone--statistics for benefits and problems].
Tidsskr Nor Laegeforen. 2007 Oct 18;127(20):2702-3.
引用本文的文献
1
Rosiglitazone and cardiovascular risk.
Curr Atheroscler Rep. 2008 Oct;10(5):398-404. doi: 10.1007/s11883-008-0062-7.
2
Rosiglitazone : a review of its use in type 2 diabetes mellitus.
Drugs. 2007;67(18):2747-79. doi: 10.2165/00003495-200767180-00008.
Zotero 插件